Immunic, Inc. (IMUX) is a clinical-stage biopharmaceutical company focused on developing oral therapies for chronic inflammatory diseases. The analysis indicates strong performance in debt and liquidity ratios, with no evident non-compliant business activities. However, insufficient data on interest and non-permissible income leads to some under-review statuses. Overall, while financial screens are favorable, the lack of index inclusion results in a non-compliant classification. Investors should monitor upcoming financial disclosures for full verification.